Meloxicam inhibits prostaglandin E2 generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach

Pharmacology

Volumn 61, Issue 4, 2000, Pages 244-250

  Ogino, Keiko ^a,c   Hatanaka, Ko ^b   Kawamura, Michiko ^b   Ohno, Takashi ^b   Harada, Yoshiteru ^c  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

Carrageenin induced pleurisy; Cyclooxygenase 2; Gastric toxicity of NSAIDs; Meloxicam

Indexed keywords

ACETYLSALICYLIC ACID; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PIROXICAM; PROSTAGLANDIN E2; PROSTANOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SELECTIVITY; GASTROINTESTINAL TOXICITY; INFLAMMATION; MALE; NONHUMAN; PLEURISY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; RAT;

EID: 0033658744     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028408     Document Type: Article

References (32)

1. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
2. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
3. Prostaglandin synthase 2
4. Mechanism of action of anti-inflammatory drugs
5. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroid anti-inflammatory agent with favourable gastrointestinal tolerance
6. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1
7. Meloxicam: Influence on arachidonic acid metabolism. 1. In vitro findings
8. Review of clinical trials and benefit/risk ratio of meloxicam
9. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis
10. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, prioxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers
11. Safety of meloxicam: A global analysis of clinical trials
12. Improvement in gastrointestinal tolerability of the selective cyclooxygenease (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Large-Scale Evaluation of COX-Inhibiting Therapies (SELECT) trial in osteoarthritis
13. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro
14. Selective inhibition by nimesulide, a novel nonsteroidal anti-inflammatory drug, with prostaglandin endoperoxide synthase-2 activity in vitro
15. 2 formation in rat carrageenin-induced pleurisy
16. Differing profiles of prostaglandin formation inhibition between selective prostaglandin H synthase-2 inhibitors and conventional NSAIDs in inflammatory and non-inflammatory sites of the rat
17. Release of endogenous prostaglandins by mild hyperosmotic saline inhibits tetragastrin-stimulated gastric acid secretion in rats
18. Changes in the levels of prostaglandins and thromboxane and their roles in the accumulation of exudate in rat carrageenin-induced pleurisy - A profile analysis using gas chromatography-mass spectrometry
19. 2 (prostacyclin) generation in vivo by a phenolic anti-inflammatory agent in the rabbit
20. Cyclooxygenase-2: Regulation and relevance in inflammation
21. Expression and function of cyclooxygenase-2 in mesothelial cells during late phase of rat carrageenin-induced pleurisy
22. 2
23. Identification of human prostaglandin E synthase: A microsomal glutathione-dependent, inducible enzyme, constituting a potential novel drug target
24. Detection of inducible prostaglandin H synthase-2 in cells in the exudate of rat carrageenin-induced pleurisy
25. Cyclooxygenase isozymes in mucosal ulcerogenic and functional responses following barrier disruption in rat stomachs
26. 14C]meloxicam in joints of rats with adjuvant arthritis
27. Selective inhibitors of cyclooxygenase-2: Are they really effective, selective, and GI-safe?
28. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity
29. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
30. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice
31. Eicosanoids and the gastrointestinal tract
32. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients